Intermittent treatment with vemurafenib may prevent lethal drug resistance in melanoma

History of epidermal stem cell use in the clinical setting

Analysing the efficacy of treatment through Response Evaluation Criteria in Solid Tumors (RECIST)

Phase III MISSION trial: Sorafenib does not extend overall survival as third or fourth line therapy in lung cancer

Trametinib and dabrafenib combination therapy against metastatic melanoma

BRAF inhibitor dabrafenib alone vs combination with MEK1/2 inhibitor trametinib for melanoma

Phase I and II trials focus on drug combination slowing development of resistance inhibiting BRAF

The immuno side of melanoma

MEK inhibitor, trametinib, improves progression free survival in melanoma

Treating metastatic melanoma with vemurafenib

New BRAF inhibitor dabrafenib delays disease progression in advanced melanoma

New MEK inhibitor, trametinib, improves survival in advanced melanoma